Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …

Purpose: Colorectal cancer is one of the most common malignancies worldwide. Recently, a
novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As miR-7, a …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

Purpose: Advanced breast cancer (ABC) has not been subjected to the same degree of
molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the …

The colorectal cancer (CRC) Subtyping Consortium has unified six independent molecular
classification systems, based on gene expression data, into a single consensus system with …

For the past decade, it has been recognized that pediatric low-grade gliomas (LGGs) and
glial-neuronal tumors carry distinct molecular alterations with resultant aberrant intracellular …

The ERK pathway is critical in oncogenesis; aberrations in components of this pathway are
common in approximately 30% of human cancers. ERK1/2 (ERK) regulates cell proliferation …